Antonio Méndez-Durán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Méndez-Durán has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Célida Duque-Molina
Instituto Mexicano del Seguro Social, Dirección de Prestaciones Médicas. Ciudad de México, México
2 shared publications Francisco Jesús Rivera-Rodríguez
2 shared publicationsGilberto Pérez-Aguilar
2 shared publicationsManuel Humberto Ignorosa-Luna
2 shared publications- Ramón Ruiz Mejia
Nephrology Service, Centro Médico ISSEMYM Lic. Arturo Montiel Rojas Metepec Mexico State, Mexico
2 shared publications - Ricardo Avilés-Hernández
Instituto Mexicano del Seguro Social, Dirección de Prestaciones Médicas, Unidad de Planeación e Innovación en Salud. Ciudad de México, México Instituto Mexicano del Seguro Social México
2 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 12
Comprehensive Management of Hyperkalaemia in Patients with Chronic Kidney Disease and Cardiovascular Conditions: Expert Recommendations from Mexico
Patients with chronic kidney disease and/or cardiovascular disease are at heightened risk of developing hyperkalaemia. This electrolyte disorder is prevalent and, if left untreated, typically results in fatal outcomes. The implementation of standardised, specialised management strategies represents a valuable tool for clinicians in the care of these patients. The primary objective of this study is to present a consensus document for the management of hyperkalaemia of cardiorenal origin, developed by a group of experts in cardiology and nephrology, opinion leaders in Mexico. To this end, a Delphi panel was formed, comprising a group of cardiologists and a group of nephrologists, each coordinated by a leader who concentrated the information. The panellists responded to a questionnaire that was sent to them. In a virtual meeting, the responses were reviewed and a consensus was reached by all participants based on the current literature.
- 29 April 2026
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 12
Open AccessComprehensive Management of Hyperkalaemia in Patients with Chronic Kidney Disease and Cardiovascular Conditions: Expert Recommendations from Mexico
Patients with chronic kidney disease and/or cardiovascular disease are at heightened risk of developing hyperkalaemia. This electrolyte disorder is prevalent and, if left untreated, typically results in fatal outcomes. The implementation of standardised, specialised management strategies represents a valuable tool for clinicians in the care of these patients. The primary objective of this study is to present a consensus document for the management of hyperkalaemia of cardiorenal origin, developed by a group of experts in cardiology and nephrology, opinion leaders in Mexico. To this end, a Delphi panel was formed, comprising a group of cardiologists and a group of nephrologists, each coordinated by a leader who concentrated the information. The panellists responded to a questionnaire that was sent to them. In a virtual meeting, the responses were reviewed and a consensus was reached by all participants based on the current literature.
- Open Access
- 28 November 2025
- Published by Instituto Mexicano del Seguro Social in Nefrología Mexicana
- Vol. 46 (4)
Cáncer y enfermedad renal crónica, un enfoque al cáncer renal
Resumen Actualmente el nefrólogo atiende a un mayor número de pacientes oncológicos, entre los que el cáncer renal no es la excepción. El equipo interdisciplinario constituye un pilar fundamental en la terapéutica integral, sobre todo cuando hay que tomar la decisión de iniciar una terapia dialítica. El cáncer renal representa del 2 al 3% de todos los cánceres, su mayor incidencia se observa en países occidentales, es la lesión sólida renal más frecuente y representa hasta el 90% de los tumores renales malignos. Se observa una mayor frecuencia en hombres que en mujeres, y de 60 y 70 años de edad. Al igual que el resto de los cánceres, no se conoce un agente causal, algunos factores estrechamente relacionados con su desarrollo son el tabaquismo, la obesidad y la hipertensión arterial. Desafortunadamente, como en la mayoría de las neoplasias malignas el cáncer renal cursa de manera asintomática, más allá de la tríada clásica, no genera subrogados que permitan su identificación y el diagnóstico por imagen cobra importancia. Al momento se dispone de una gran variedad de agentes farmacológicos para su tratamiento.
- 28 November 2025
- Published by Instituto Mexicano del Seguro Social in Nefrología Mexicana
- Vol. 46 (4)
Open AccessCáncer y enfermedad renal crónica, un enfoque al cáncer renal
Resumen Actualmente el nefrólogo atiende a un mayor número de pacientes oncológicos, entre los que el cáncer renal no es la excepción. El equipo interdisciplinario constituye un pilar fundamental en la terapéutica integral, sobre todo cuando hay que tomar la decisión de iniciar una terapia dialítica. El cáncer renal representa del 2 al 3% de todos los cánceres, su mayor incidencia se observa en países occidentales, es la lesión sólida renal más frecuente y representa hasta el 90% de los tumores renales malignos. Se observa una mayor frecuencia en hombres que en mujeres, y de 60 y 70 años de edad. Al igual que el resto de los cánceres, no se conoce un agente causal, algunos factores estrechamente relacionados con su desarrollo son el tabaquismo, la obesidad y la hipertensión arterial. Desafortunadamente, como en la mayoría de las neoplasias malignas el cáncer renal cursa de manera asintomática, más allá de la tríada clásica, no genera subrogados que permitan su identificación y el diagnóstico por imagen cobra importancia. Al momento se dispone de una gran variedad de agentes farmacológicos para su tratamiento.
- Open Access
- 3 September 2025
- Published by Instituto Mexicano del Seguro Social in Nefrología Mexicana
- Vol. 46 (3)
Nefrología Mexicana, 45 aniversario
- 3 September 2025
- Published by Instituto Mexicano del Seguro Social in Nefrología Mexicana
- Vol. 46 (3)
Open AccessNefrología Mexicana, 45 aniversario
- Open Access
- 29 May 2024
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 11 (2)
Tricarboxylic Cycle Intermediates in Combination with Calcium Phosphate Chelators and Sodium Bicarbonate Increases eGFR in Patients with Stages 3b, 4 and 5 CKD: A Retrospective Observational Study
Introduction: Currently, the conservative management of chronic kidney disease (CKD) involves treating the primary disease and its consequences, as well as improving altered biochemical markers. Evidence suggests that the key management strategy for slowing down the progression of the disease is nephroprotection. Objective: This study aimed to evaluate the effect of the supply of TCA cycle intermediates in combination with calcium carbonate, calcium lactate, and sodium bicarbonate in patients with CKD. Methodology: A retrospective observational study was undertaken in nephrology and internal medicine clinics in Mexico. The study enrolled patients aged over 18 with stages 3b, 4, and 5 chronic kidney disease (CKD) who were not undergoing renal replacement therapy (RRT) and had received treatment based on TCA therapy. Results: The study included a total of 55 patients with CKD. The results showed an increase in eGFR from a baseline average of 16.73 ± 1,374 mL/min to a final average of 19.18 ± 1,516 mL/min and a decrease in creatinine values from a baseline average of 4.26 ± 2.44 mg/dL to a final average of 3.77 ± 2.23 mg/dL. These changes had a statistical significance P?0.05.Conclusions: The observed benefits of TCA in combination with sodium bicarbonate, calcium carbonate, and calcium lactate include: 1) Increased eGFR, 2) Decreased serum creatinine, 3) Decreased serum urea, 4) Decreased serum phosphorus, 5) Increased serum hemoglobin, and 6) Maintenance of albumin levels within normal ranges. Adjuvant therapy with the combination of TCA could be a useful tool as a new therapeutic option in patients with CKD.
- 29 May 2024
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 11 (2)
Open AccessTricarboxylic Cycle Intermediates in Combination with Calcium Phosphate Chelators and Sodium Bicarbonate Increases eGFR in Patients with Stages 3b, 4 and 5 CKD: A Retrospective Observational Study
Introduction: Currently, the conservative management of chronic kidney disease (CKD) involves treating the primary disease and its consequences, as well as improving altered biochemical markers. Evidence suggests that the key management strategy for slowing down the progression of the disease is nephroprotection. Objective: This study aimed to evaluate the effect of the supply of TCA cycle intermediates in combination with calcium carbonate, calcium lactate, and sodium bicarbonate in patients with CKD. Methodology: A retrospective observational study was undertaken in nephrology and internal medicine clinics in Mexico. The study enrolled patients aged over 18 with stages 3b, 4, and 5 chronic kidney disease (CKD) who were not undergoing renal replacement therapy (RRT) and had received treatment based on TCA therapy. Results: The study included a total of 55 patients with CKD. The results showed an increase in eGFR from a baseline average of 16.73 ± 1,374 mL/min to a final average of 19.18 ± 1,516 mL/min and a decrease in creatinine values from a baseline average of 4.26 ± 2.44 mg/dL to a final average of 3.77 ± 2.23 mg/dL. These changes had a statistical significance P?0.05.Conclusions: The observed benefits of TCA in combination with sodium bicarbonate, calcium carbonate, and calcium lactate include: 1) Increased eGFR, 2) Decreased serum creatinine, 3) Decreased serum urea, 4) Decreased serum phosphorus, 5) Increased serum hemoglobin, and 6) Maintenance of albumin levels within normal ranges. Adjuvant therapy with the combination of TCA could be a useful tool as a new therapeutic option in patients with CKD.
- Open Access
- 4 April 2024
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 8 (2) , 6592-6605
Diálisis Peritoneal Automatizada: Una Modalidad con Grandes Beneficios y Grandes Retos
Introducción: Bajo el precepto global de la OMS “no dejar a nadie atrás”, evitar desigualdad y favorecer la inclusión, se implementó una estrategia para favorecer el uso de Diálisis Peritoneal Automatizada en población vulnerable. Material y métodos: Estudio prospectivo de 24 semanas de seguimiento. Identifica unidad médica, pacientes de nuevo ingreso y conversiones, género y edad. Estima 3 escenarios hipotéticos de optimización de costos. Resultados: 962 pacientes, 633 incidentes (65.8%) y 329 convertidos (34.2%), 597 masculinos (62%) y 365 femeninos (38%), con edad promedio 53.3 años (rango: 3 a 87), el grupo más prevalente fue de 41 a 60 años con 392 casos (40.7%). 268 pacientes fueron >65 años de edad (27.8%). Los criterios de ingreso fueron transporte peritoneal alto 172 (17.8%), transporte bajo 21 (2.2%), trabajador activo 391 (40.6%), red de apoyo frágil 317 (32.9%), estudiante 26 (2.7%), ausencia de cuidador 20 (2.3%), otros 15 (1.6%). Los costos hipotéticos con diálisis convencional para el escenario A, 769,600.00, el B, 24,964,621.50 y el C, 6,685,034.20; el escenario de ahorro de 307,840.00, 9,985,848.60 y 2,674,013.68, respectivamente; total 16,209,627.90 Conclusiones: El beneficio de la DPA mejora calidad de vida de valor incalculable. Se debe eliminar el precepto de mayor costo al analizar costos indirectos. Introduction: Under the WHO global precept “leave no one behind”, avoid inequality and promote inclusion, a strategy was implemented to promote the use of Automated Peritoneal Dialysis in vulnerable population. Material and methods: Prospective study with 24 weeks of follow-up. Identifies medical unit, newly admitted patients and conversions, gender and age. Estimate 3 hypothetical cost optimization scenarios. Results: 962 patients, 633 incident (65.8%) and 329 converted (34.2%), 597 male (62%) and 365 female (38%), with average age 53.3 years (range: 3 to 87), the most prevalent group It was from 41 to 60 years with 392 cases (40.7%). 268 patients were >65 years of age (27.8%). The entry criteria were high peritoneal transport 172 (17.8%), low transport 21 (2.2%), active worker 391 (40.6%), fragile support network 317 (32.9%), student 26 (2.7%), absence of caregiver 20 (2.3%), other 15 (1.6%). The hypothetical costs with conventional dialysis for scenario A, 769,600.00, B, 24,964,621.50 and C, 6,685,034.20; the savings scenario of 307,840.00, 9,985,848.60 and 2,674,013.68, respectively; total 16,209,627.90 Conclusions: The benefit of APD improves quality of life of incalculable value. The higher cost provision should be eliminated when analyzing indirect costs.
- 4 April 2024
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 8 (2) , 6592-6605
Open AccessDiálisis Peritoneal Automatizada: Una Modalidad con Grandes Beneficios y Grandes Retos
Introducción: Bajo el precepto global de la OMS “no dejar a nadie atrás”, evitar desigualdad y favorecer la inclusión, se implementó una estrategia para favorecer el uso de Diálisis Peritoneal Automatizada en población vulnerable. Material y métodos: Estudio prospectivo de 24 semanas de seguimiento. Identifica unidad médica, pacientes de nuevo ingreso y conversiones, género y edad. Estima 3 escenarios hipotéticos de optimización de costos. Resultados: 962 pacientes, 633 incidentes (65.8%) y 329 convertidos (34.2%), 597 masculinos (62%) y 365 femeninos (38%), con edad promedio 53.3 años (rango: 3 a 87), el grupo más prevalente fue de 41 a 60 años con 392 casos (40.7%). 268 pacientes fueron >65 años de edad (27.8%). Los criterios de ingreso fueron transporte peritoneal alto 172 (17.8%), transporte bajo 21 (2.2%), trabajador activo 391 (40.6%), red de apoyo frágil 317 (32.9%), estudiante 26 (2.7%), ausencia de cuidador 20 (2.3%), otros 15 (1.6%). Los costos hipotéticos con diálisis convencional para el escenario A, 769,600.00, el B, 24,964,621.50 y el C, 6,685,034.20; el escenario de ahorro de 307,840.00, 9,985,848.60 y 2,674,013.68, respectivamente; total 16,209,627.90 Conclusiones: El beneficio de la DPA mejora calidad de vida de valor incalculable. Se debe eliminar el precepto de mayor costo al analizar costos indirectos. Introduction: Under the WHO global precept “leave no one behind”, avoid inequality and promote inclusion, a strategy was implemented to promote the use of Automated Peritoneal Dialysis in vulnerable population. Material and methods: Prospective study with 24 weeks of follow-up. Identifies medical unit, newly admitted patients and conversions, gender and age. Estimate 3 hypothetical cost optimization scenarios. Results: 962 patients, 633 incident (65.8%) and 329 converted (34.2%), 597 male (62%) and 365 female (38%), with average age 53.3 years (range: 3 to 87), the most prevalent group It was from 41 to 60 years with 392 cases (40.7%). 268 patients were >65 years of age (27.8%). The entry criteria were high peritoneal transport 172 (17.8%), low transport 21 (2.2%), active worker 391 (40.6%), fragile support network 317 (32.9%), student 26 (2.7%), absence of caregiver 20 (2.3%), other 15 (1.6%). The hypothetical costs with conventional dialysis for scenario A, 769,600.00, B, 24,964,621.50 and C, 6,685,034.20; the savings scenario of 307,840.00, 9,985,848.60 and 2,674,013.68, respectively; total 16,209,627.90 Conclusions: The benefit of APD improves quality of life of incalculable value. The higher cost provision should be eliminated when analyzing indirect costs.
- Open Access
- 4 September 2023
- Vol. 61 (5) , 631-637
Renoprotección. A propósito del Día Mundial del Riñón
El Día Mundial del Riñón se fundó en el año 2003 por el doctor Joel D. Kopple, nefrólogo norteamericano, quien en el pleno del Congreso de la Federación Internacional de Fundaciones Renales expuso la necesidad de implementar la celebración en un día que aludiera a este órgano, con el fin de dirigir acciones de prevención para la enfermedad renal y concientizar a la comunidad médica y a la población en general de la importancia de cuidar los riñones. Tres años después, la propuesta fue aceptada y a partir del 2006 se celebra el Día Mundial del Riñón. La difusión se encuentra en todo el mundo y en cada lugar se desarrollan pláticas, cursos, talleres, actividades culturales y hasta maratones relacionados con la prevención, el diagnóstico y el tratamiento de la enfermedad renal. La enfermedad renal crónica (ERC) es un trastorno de evolución crónica, degenerativa y letal. Su atención demanda gran cantidad de recursos humanos, financieros y de infraestructura. Es una enfermedad que deteriora la calidad de vida y afecta negativamente la supervivencia. Por otra parte, conduce a realizar tratamientos costosos de diálisis y trasplante renal que ponen en riesgo financiero a cualquier institución de salud, sobre todo a aquellas más vulnerables. La idea principal de estos organismos internacionales sin fines de lucro es promover el bienestar y mejorar la calidad de vida de las personas con ERC con y sin diálisis, y promover el trasplante renal como primer opción de tratamiento.
- 4 September 2023
- Vol. 61 (5) , 631-637
Open AccessRenoprotección. A propósito del Día Mundial del Riñón
El Día Mundial del Riñón se fundó en el año 2003 por el doctor Joel D. Kopple, nefrólogo norteamericano, quien en el pleno del Congreso de la Federación Internacional de Fundaciones Renales expuso la necesidad de implementar la celebración en un día que aludiera a este órgano, con el fin de dirigir acciones de prevención para la enfermedad renal y concientizar a la comunidad médica y a la población en general de la importancia de cuidar los riñones. Tres años después, la propuesta fue aceptada y a partir del 2006 se celebra el Día Mundial del Riñón. La difusión se encuentra en todo el mundo y en cada lugar se desarrollan pláticas, cursos, talleres, actividades culturales y hasta maratones relacionados con la prevención, el diagnóstico y el tratamiento de la enfermedad renal. La enfermedad renal crónica (ERC) es un trastorno de evolución crónica, degenerativa y letal. Su atención demanda gran cantidad de recursos humanos, financieros y de infraestructura. Es una enfermedad que deteriora la calidad de vida y afecta negativamente la supervivencia. Por otra parte, conduce a realizar tratamientos costosos de diálisis y trasplante renal que ponen en riesgo financiero a cualquier institución de salud, sobre todo a aquellas más vulnerables. La idea principal de estos organismos internacionales sin fines de lucro es promover el bienestar y mejorar la calidad de vida de las personas con ERC con y sin diálisis, y promover el trasplante renal como primer opción de tratamiento.
- Open Access
- 19 April 2021
- Published by Nepal Journals Online (JOL) in International Journal of Occupational Safety and Health
- Vol. 11 (1) , 54-64
Health-associated infections and COVID-19 in Mexico: safety and health rules at work or job biosecurity?
The pandemic caused by COVID-19 has grown exponentially from the first reports from China in December 2019 to November 2020. Cases have been reported in more than 180 countries, totaling more than 61.8 million cases of COVID-19 throughout the world and more than 1.4 million deaths. Health personnel, being exposed to the care of COVID-19 patients with high viral load, have the risk of developing infections associated with health care, their high morbidity and mortality being of multifactorial origin. Given that the term Biosafety and Occupational Biosafety has been used internationally, this term does not have wide acceptance in the scientific community and in the case of Mexico it is not referred to and it is not defined in the Mexican legal framework or current regulations. Far from being handled and understood as an isolated concept, this term should be referred to as multiple concepts, being recommended in the workplace in Mexico not to use it, suggesting referring to the Safety and Health Regulations at Work, whose mandatory application will allow reducing healthcare-associated infections.
- 19 April 2021
- Published by Nepal Journals Online (JOL) in International Journal of Occupational Safety and Health
- Vol. 11 (1) , 54-64
Open AccessHealth-associated infections and COVID-19 in Mexico: safety and health rules at work or job biosecurity?
The pandemic caused by COVID-19 has grown exponentially from the first reports from China in December 2019 to November 2020. Cases have been reported in more than 180 countries, totaling more than 61.8 million cases of COVID-19 throughout the world and more than 1.4 million deaths. Health personnel, being exposed to the care of COVID-19 patients with high viral load, have the risk of developing infections associated with health care, their high morbidity and mortality being of multifactorial origin. Given that the term Biosafety and Occupational Biosafety has been used internationally, this term does not have wide acceptance in the scientific community and in the case of Mexico it is not referred to and it is not defined in the Mexican legal framework or current regulations. Far from being handled and understood as an isolated concept, this term should be referred to as multiple concepts, being recommended in the workplace in Mexico not to use it, suggesting referring to the Safety and Health Regulations at Work, whose mandatory application will allow reducing healthcare-associated infections.
- Open Access
- 1 January 2021
- Published by Elsevier in Nefrología (English Edition)
- Vol. 41 (1) , 82-83
Evolution of renal replacement therapy in Mexico in the last 10 years
- 1 January 2021
- Published by Elsevier in Nefrología (English Edition)
- Vol. 41 (1) , 82-83
Open AccessEvolution of renal replacement therapy in Mexico in the last 10 years
- Open Access
- 1 January 2021
- Published by Elsevier in Nefrología
- Vol. 41 (1) , 82-83
Evolución del tratamiento sustitutivo de la función renal en México en los últimos 10 años
- 1 January 2021
- Published by Elsevier in Nefrología
- Vol. 41 (1) , 82-83
Open AccessEvolución del tratamiento sustitutivo de la función renal en México en los últimos 10 años
- 15 June 2018
- Vol. 56 (2) , 163-166
The Instituto Mexicano del Seguro Social gives dialysis therapies to 426 students without cost
The Instituto Mexicano del Seguro Social (IMSS) is the institution with the greatest health coverage in Mexico. In adherence to existing and committed to provide specialized services to specific populations (vulnerable age groups, such as children and young people in primary, secondary and higher education, productive and without social security educational training), this gives the renal replacement therapy -peritoneal dialysis and hemodialysis- at no cost to students. Cross-sectional and retrospective study conducted from 1 to 30 September 2016; Census Patients with Chronical Renal Failure, sociodemographic and type of therapy are identified; direct costs are estimated. At 25 August 2016 to 16 426 was addressed to 26 years old, 279 male (65%) and 147 female (35%). The causes IRC were congenital problems 194 (45%), chronic glomerular diseases 111 (26%), diabetes mellitus type 1, 58 (14%), polycystic kidneys 7 (2%) and undetermined causes 56 (13%). 78 patients received CAPD, APD 208, 61 HD and 79 HD IM MS. The average annual investment per patient was 75 827.47 mexican pesos; the costs were in CAPD dialysis modality $ 41 931.20, DPA $ 64 123.20, HD intramural $ 33 301.32 and extramural $ 165 360.00; which generated a cash cost of $ 32 302 503.40 mexican pesos These data demonstrate the Institute commitment to society in granting health, preserve life and improve the quality of life of Mexicans and stage of health risk posed by the IRC.- 15 June 2018
- Vol. 56 (2) , 163-166
The Instituto Mexicano del Seguro Social gives dialysis therapies to 426 students without cost
The Instituto Mexicano del Seguro Social (IMSS) is the institution with the greatest health coverage in Mexico. In adherence to existing and committed to provide specialized services to specific populations (vulnerable age groups, such as children and young people in primary, secondary and higher education, productive and without social security educational training), this gives the renal replacement therapy -peritoneal dialysis and hemodialysis- at no cost to students. Cross-sectional and retrospective study conducted from 1 to 30 September 2016; Census Patients with Chronical Renal Failure, sociodemographic and type of therapy are identified; direct costs are estimated. At 25 August 2016 to 16 426 was addressed to 26 years old, 279 male (65%) and 147 female (35%). The causes IRC were congenital problems 194 (45%), chronic glomerular diseases 111 (26%), diabetes mellitus type 1, 58 (14%), polycystic kidneys 7 (2%) and undetermined causes 56 (13%). 78 patients received CAPD, APD 208, 61 HD and 79 HD IM MS. The average annual investment per patient was 75 827.47 mexican pesos; the costs were in CAPD dialysis modality $ 41 931.20, DPA $ 64 123.20, HD intramural $ 33 301.32 and extramural $ 165 360.00; which generated a cash cost of $ 32 302 503.40 mexican pesos These data demonstrate the Institute commitment to society in granting health, preserve life and improve the quality of life of Mexicans and stage of health risk posed by the IRC.